Warning
Teva Pharmaceuticals USA Recalls Amoxicillin and Clavulanate Potassium for Oral Suspension
This is a Class II recall. This product may cause temporary health problems or pose a slight threat of a serious nature.
Source: FDA
WarningRecall #D-0151-2026Drug / Pharmaceutical
Teva Pharmaceuticals USA Recalls Amoxicillin and Clavulanate Potassium for Oral Suspension
Teva Pharmaceuticals USA, Inc · Class II — Moderate Risk
Product Description
Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), Rx only, manufactured in Canada by: Teva Canada Limited, Toronto, Canada M1B 2K9; Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054 NDC 0093-2277-7.
Reason for Recall
Subpotent drug; Clavulanate Potassium component
FDA Classification
Class II — Moderate Risk
A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Distribution
Distributed in three (3) States: MS, OH, CA.
Remedy
Consumers should stop using this product. Contact the recalling firm for further instructions regarding this product.
411 Press Analysis
Teva Pharmaceuticals USA, Inc has recalled a pharmaceutical product that the FDA classified as Class II affecting 4680 cartons. The recall was initiated on October 13, 2025. Subpotent drug; Clavulanate Potassium component. It was distributed nationwide. Class II recalls involve products that might cause a temporary health problem or pose only a slight threat of a serious nature. Consumers should discontinue use and contact the firm.
Sources: FDA openFDA Enforcement Database
This recall appears in: Drug & Medication Defects and Teva Pharmaceuticals USA recalls.